**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

Single Technology Appraisal (STA)

Azacitidine for the treatment of myelodysplastic syndrome and acute myeloid leukaemia

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

**Version of matrix of consultees and commentators reviewed:**
Provisional matrix of consultees and commentators sent for consultation

**Summary of comments, action taken, and justification of action:**

<table>
<thead>
<tr>
<th>Proposal:</th>
<th>Proposal made by:</th>
<th>Action taken:</th>
<th>Justification:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Proposed the following organisation; UK MDS Forum Patient Forum Dr Sally Killick</td>
<td>Royal College of Physicians</td>
<td>Added</td>
</tr>
<tr>
<td>2.</td>
<td>Noted that the manufacturer of the drug are Celgene formerly Pharmion, but never Pfizer.</td>
<td></td>
<td>Added</td>
</tr>
</tbody>
</table>

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Azacitidine for the treatment of myelodysplastic syndrome and acute myeloid leukaemia

Issue date: December 2008